SMA Press
ProteinTech Interview with The Spinal Muscular Atrophy Foundation
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disease characterized by motor neuron loss and muscle atrophy and weakness. The disease is caused by deletion or mutational inactivation of the SMN1 gene that encodes survival of motor neuron (SMN) protein, critical to motor neuron health and survival. The disease typically presents in early infancy and…
Read MoreBiogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy
Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy — Biogen Idec has Option to Develop and Commercialize Promising Compound for Most Common Genetic Cause of Infant Mortality — — Biogen Idec’s Expertise in Neurology to Aid in Rapid Development of ISIS-SMNRx — SMA is a genetic neuromuscular disease characterized…
Read MoreBiogen May Spend as Much as $299 Million on Isis Treatment for Children
Biogen May Spend as Much as $299 Million on Isis Treatment for Children Bloomberg News by Robert Langreth January 4, 2012 Biogen Idec Inc. (BIIB) will gain Isis Pharmaceuticals Inc. (ISIS)’s drug for an inherited muscle-weakening disease that afflicts children, in a development deal that may cost as much as $299 million. Biogen, the world’s biggest maker…
Read MoreSalvar a Arya
El País by Sandro Pozzi December 26, 2011 Las cifras ayudan a entender la batalla que libran Dinakar Singh y Loren Eng, millonario y exsocio del banco Goldman Sachs, y su esposa, Loren Eng, por su hija Arya. Entre los más de 312 millones de habitantes de EE UU, solo 9.000 tiene la enfermedad infantil…
Read MoreIsis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients with Spinal Muscular Atrophy
CARLSBAD, Calif., December 19, 2011 – Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Isis is developing ISIS-SMNRx as a potential treatment for all…
Read MoreRoche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Collaboration offers new hope for a potential treatment for the leading genetic cause of death in infants and toddlers Basel, Switzerland, South Plainfield, NJ, USA and New York, NY, USA – November 29, 2011 – Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for…
Read More